# A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants

> **NCT02343289** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Esketamine
- **DRUG:** Clarithromycin

## Key facts

- **NCT ID:** NCT02343289
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343289, "A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02343289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*